Useful in the initial evaluation of neuromyelitis optica (NMO) spectrum disorders. This test uses a cell-based assay (CBA) to detect antibodies against aquaporin-4.
Semi-Quantitative Cell-Based Indirect Fluorescent Antibody
Mon, Wed, Fri
New York DOH Approval Status
Transfer 0.5 mL CSF to an ARUP Standard Transport Tube. (Min: 0.15 mL)
Hemolyzed, contaminated specimens or severely lipemic specimens.
Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year
Less than 1:1
Diagnosis of neuromyelitis optica (NMO) requires the presence of longitudinally extensive acute myelitis (lesions extending over 3 or more vertebral segments) and optic neuritis. Approximately 75 percent of patients with NMO express antibodies to the aquaporin-4 (AQP4) receptor. While the absence of AQP4 receptor antibodies does not rule out a diagnosis of NMO, presence of this antibody is diagnostic for NMO.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Laboratory Developed Test (LDT)
If AQP4 antibody IgG is positive, then an AQP4 antibody IgG titer is reported. Additional charges apply.
86052; if reflexed, add 86256
|Component Test Code*||Component Chart Name||LOINC|
|2011700||Neuromyelitis Optica/AQP4-IgG, CSF||46718-3|
- AQP4 antibody
- Aquaporin; Devic's Ab
- Cell-based assay
- Cell-binding assay
- CNS demyelinating disease
- Devic's Antibody
- Neuromyelitis Optica (NMO) Antibody
- Neuromyelitis Optica IgG
- Optic Neuritis Ab
- Optic Neuritis Antibody
- Optic-Spinal MS Antibody
- Pediatric CNS disorders
- Transverse Myelitis Ab
- Vision Loss Ab